Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics. Computational structure-based design is combined with automated, fully synthetic chemistry. In the computational design workflow, large virtual libraries of diverse macrocycles for intrinsic cell permeability and target affinity are generated and screened. Circle Pharma’s technology allows them to target intracellular targets such as protein-protein interactions and achieve oral bioavailability. The automated chemistry synthesis is used to assess in parallel multiple design hypotheses for a given target and rapidly explore structure activity relationships. Circle Pharma is initially focused on intracellular protein-protein interactions that drive oncology pathways.
Circle Pharma, Inc. today announced that results from its collaborative work with Pfizer Inc. to develop a potent and orally bioavailable macrocycle modulator of the chemokine receptor, CXCR7, have been published in the Journal of Medicinal Chemistry.
Circle Pharma, Inc. today announced that it has completed an expansion of its Series A financing, with new investors WI Harper Group, Elements Partners, LLC, Whitesun Healthcare Ventures Limited and LifeForce Capital joining the round.
David C. Spellmeyer, PhD
Interim Chief Scientific Officer
David J. Earp, J.D., Ph.D.
Matthew P. Jacobson, Ph.D.
Co-Founder, SAB Member
R. Scott Lokey, Ph.D.
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators. - PubMed - NCBI
pubmeddev, Boehm M , et al.
Peptide Therapeutics Near the Sweetest Spots
March 29, 2018